brilacidin
Phase 2- Indications
- Acute bacterial skin and skin structure infections
Company intelligence / Profile preview
PolyMedix was a clinical-stage biotechnology company developing small-molecule drugs that mimic the activity of host defense proteins for infectious diseases and innate immunity disorders. Its lead compound Brilacidin demonstrated safety and efficacy in a Phase 2a trial for ABSSSI caused by Staphylococcus aureus (including MRSA), outperforming the control arm. Another program targeted anticoagulant reversal with PMX‑60056. The company filed for bankruptcy and its assets—including nine compounds—were acquired by Cellceutix Corporation in September 2013.[1][5]
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on PolyMedix, Inc..